Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Mereo BioPharma Group plcNASDAQ: MREO

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of -555.2% for the fiscal year ending Dec 2026, up from -8375.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-8375.6%— YoY
LTMMar 2026
-7139.7%— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—+2886.5 pp—
1 year—+7820.4 pp—
3 years—+8260.0 pp—
5 years+8371.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-8375.6%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How MREO compares with its peers on the latest reported figures

  • MREO's LTM Mar 2026 net margin of -7139.7% is the 4th highest of the 5 companies compared; the peer median is -1503.4%.
MREO Competitors Peer median
Net Margin for MREO and competitors
Company Period LTM level YoY 3-year change
PRQRProQR Therapeutics N.V.LTM Mar 2026-339.4% -180.3 pp+1527.3 pp
IMMPImmutep LimitedFY2025-1218.0% -106.2 pp+17688.5 pp
ACIUAC Immune S.A.LTM Mar 2026-1788.8% -1604.7 pp-173.6 pp
MREOMereo BioPharma Group plcLTM Mar 2026-7139.7% ——
SLNSilence Therapeutics plcLTM Mar 2026-9243.0% —-15619.4 pp
CADLCandel Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
KYTXKyverna Therapeutics, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding MREO) -1503.4%-180.3 pp+676.9 pp

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.